Marinus Pharmaceuticals (MRNS) PT Lowered to $22 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Marinus Pharmaceuticals (MRNS) PT Lowered to $12 at Oppenheimer
November 9, 2022 7:59 AM ESTOppenheimer analyst Jay Olson lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $12.00 (from $23.00) while maintaining a Outperform rating.... More
Marinus Pharmaceuticals (MRNS) PT Lowered to $27 at H.C. Wainwright
November 9, 2022 7:15 AM ESTH.C. Wainwright analyst Douglas Tsao lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $27.00 (from $38.00) while maintaining a Buy rating.... More
Marinus Pharma (MRNS) Prices 10.53M Share Offering at $4.75/sh
November 8, 2022 5:40 AM ESTMarinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering price of $4.75 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 2,105,264 shares of common stock at a price of $4.749 per pre-funded warrant, for gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and offering expenses payable by Marinus. The purchase price per share of each pre-funded warrant... More
Marinus Pharma (MRNS) Announces Proposed Public Offering
November 7, 2022 4:23 PM ESTMarinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities. All of the securities to be sold in the offering are being offered by Marinus. In addition, Marinus... More
